Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Autologous Dendritic Cells in Refractory CRC
NCT05518032Phase 2Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ST-alphaDC1 in colorectal cancer (CRC), sponsored by Roswell Park Comprehensive Cancer Center. Planned start Oct 2024; status: withdrawn.
02
Drugs
ST-alphaDC1
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05518032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518032.